Physician profile
John D Sheppard
NPI 1588663702
$1,121,960.62
in general payments reported to CMS, 2019-2025
48 companies · $379K in 2025
The $379K reported for 2025 was more than what 99% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $106K · 2020: $69K · 2021: $120K · 2022: $139K · 2023: $105K · 2024: $205K · 2025: $379K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $220K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $204K · Consulting Fee: $159K · Travel and Lodging: $78K · Food and Beverage: $19K · Honoraria: $8,403 · Gift: $40.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $219,956.25 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $204,068.88 |
| Consulting Fee | $158,530.46 |
| Travel and Lodging | $77,817.13 |
| Food and Beverage | $19,376.94 |
| Honoraria | $8,403.00 |
| Gift | $40.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $372,290.27 | 2020-2025 | Acthar |
| Bausch & Lomb Americas INC. | $253,229.21 | 2022-2025 | Miebo, Xiidra, Stellaris Elite |
| Dompe US, INC. | $142,004.54 | 2019-2025 | Oxervate |
| Biotissue Holdings INC. | $56,118.39 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $40,804.06 | 2019-2025 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $37,725.77 | 2019-2021 | |
| Alcon Vision LLC | $36,526.79 | 2019-2025 | Tryptyr, Clareon, Centurion |
| Oyster Point Pharma, INC. | $31,632.38 | 2022-2024 | Tyrvaya |
| Abbvie INC. | $23,971.38 | 2022-2025 | Vuity, Alphagan P, Lumigan |
| Mallinckrodt Enterprises LLC | $23,908.59 | 2019 | |
| Kala Pharmaceuticals, INC. | $13,552.60 | 2019-2022 | |
| Alcon Research LLC | $11,500.00 | 2024-2025 | Tryptyr |
| Novartis Pharmaceuticals Corporation | $9,740.92 | 2019-2024 | |
| Rayner Intraocular Lenses Limited | $6,454.87 | 2022-2025 | Rayone Emv, Rayone Aspheric, Rayone Spheric |
| Tarsus Pharmaceuticals, INC. | $6,381.51 | 2024-2025 | Xdemvy |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $6,381.49 | 2019-2020 | |
| Dompe Farmaceutici S.P.A. | $4,689.92 | 2024-2025 | |
| Shire North American Group INC | $4,447.56 | 2019 | |
| Harrow Eye, LLC | $4,101.96 | 2023-2025 | Vevye |
| Eyepoint US, INC. | $3,910.04 | 2019-2021 | |
| Allergan, INC. | $3,658.27 | 2019-2022 | |
| Thea Pharma INC. | $2,856.52 | 2023-2025 | Iyuzeh |
| Horizon Therapeutics Plc | $2,736.23 | 2019-2023 | Tepezza, Uplizna |
| Apellis Pharmaceuticals, INC. | $2,676.83 | 2022-2025 | Syfovre, Syfovre |
| Ani Pharmaceuticals, INC. | $2,665.93 | 2025 | Purified Cortrophin Gel |
| Kowa Research Institute, INC. | $2,625.00 | 2019-2020 | |
| Quidel Corporation | $2,612.65 | 2019-2021 | |
| Amgen INC. | $2,285.02 | 2024-2025 | Tepezza |
| Aerie Pharmaceuticals, INC. | $2,109.66 | 2019-2021 | |
| Sight Sciences, INC. | $2,017.58 | 2021-2022 | |
| Glaukos Corporation | $1,805.98 | 2020-2025 | Idosetr, Radius, Ce-Marked Kxla System |
| Ocular Therapeutix, INC. | $1,519.41 | 2021-2025 | Dextenza |
| Omeros Corporation | $1,056.10 | 2019 | |
| Tearlab Corp | $500.00 | 2019 | |
| Lensar, INC. | $397.93 | 2019-2023 | Lensar Laser System |
| New World Medical,INC. | $304.12 | 2019-2023 | |
| Vertex Pharmaceuticals Incorporated | $206.67 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $185.80 | 2024-2025 | Eylea Hd |
| Carl Zeiss Meditec USA, INC. | $102.74 | 2021 | |
| Carl Zeiss Meditec, INC. | $79.70 | 2019 | |
| Ivantis, INC | $48.09 | 2020 | |
| Halozyme INC | $46.19 | 2019-2023 | |
| Johnson & Johnson Vision Care, INC. | $37.69 | 2023 | Tecnis Simplicity |
| Johnson & Johnson Surgical Vision, INC. | $18.80 | 2022 | |
| Alimera Sciences, INC. | $18.23 | 2024 | Yutiq, Iluvien |
| Rxsight INC | $17.23 | 2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$3,043.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
$249,904.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Sheppard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.